Compare Inovio Pharmaceuticals Inc (INO) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs United States Natural Gas Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while United States Natural Gas Fund trades at $11.04 (market cap $517.27M). The key difference: United States Natural Gas Fund is far larger — about 4.6× Inovio Pharmaceuticals Inc's market cap, and United States Natural Gas Fund is more actively traded (29,485,537 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and United States Natural Gas Fund for 22 Days on average.
| INO | UNG | |
|---|---|---|
Market Cap | $112.19M | $517.27M |
Volume | 3,201,278 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $2.65 | $16.90 |
52-Week Low | $0.66 | $9.63 |
Typical Hold Time | 43 Days | 22 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
UNG trades at $11.10, up 0.63% with a bullish technical signal from moving averages. The fund shows strong profitability with $65.15M net income for 2024, though revenue remains at $0.00. Recent news highlights natural gas market volatility with record production levels and geopolitical tensions affecting energy prices. The fund maintains a solid balance sheet with $594.68M in current assets and minimal liabilities.
Investment outlook remains cautiously optimistic given bullish technical indicators and strong profitability metrics. Key risks include natural gas price volatility and geopolitical factors affecting energy markets. The absence of traditional valuation metrics requires careful monitoring of underlying commodity trends for informed positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
